<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36224711</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Molecular evolution and antigenic drift of type 3 iVDPVs excreted from a patient with immunodeficiency in Ningxia, China.</ArticleTitle><Pagination><StartPage>e28215</StartPage><MedlinePgn>e28215</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28215</ELocationID><Abstract><AbstractText>A 2.5-year-old pediatric patient with acute flaccid paralysis was diagnosed with primary immunodeficiency (PID) in Ningxia Province, China, in 2011. Twelve consecutive stool specimens were collected from the patient over a period of 10 months (18 February 2011 to 20 November 2011), and 12 immunodeficiency vaccine-derived poliovirus (iVDPV) strains (CHN15017-1 to CHN15017-12) were subsequently isolated. Nucleotide sequencing analysis of the plaque-purified iVDPVs revealed 2%-3.5% VP1-region differences from their parental Sabin 3 strain. Full-length genome sequencing showed they were all Sabin 3/Sabin 1 recombinants, sharing a common 2C-region crossover site, and the two key determinants of attenuation (U472C in the 5' untranslated region and T2493C in the VP1 region) had reverted. Temperature-sensitive experiments demonstrated that the first two iVDPV strains partially retained the temperature-sensitive phenotype's nature, while the subsequent ten iVDPV strains distinctly lost it, possibly associated with increased neurovirulence. Nineteen amino-acid substitutions were detected between 12 iVDPVs and the parental Sabin strain, of which only one (K1419R) was found on the subsequent 10 iVDPV isolates, suggesting this site's potential as a temperature-sensitive determination site. A Bayesian Monte Carlo Markov Chain phylogenetic analysis based on the P1 coding region yielded a mean iVDPV evolutionary rate of 1.02&#x2009;&#xd7;&#x2009;10<sup>-2</sup> total substitutions/site/year, and the initial oral-polio-vaccine dose was presumably administered around June 2009. Our findings provide valuable information regarding the genetic structure, high-temperature growth sensitivity, and antigenic properties of iVDPVs following long-term evolution in a single PID patient, thus augmenting the currently limited knowledge regarding the dynamic changes and evolutionary pathway of iVDPV populations with PID during long-term global replication.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1887-9776</Identifier><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of HIV/AIDS Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jiangtao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan City, Ningxia Hui Autonomous Region, Yinchuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan City, Ningxia Hui Autonomous Region, Yinchuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7053-3836</Identifier><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongyan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shuangli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ningxia Hui Autonomous Region Center for Disease Control and Prevention, Yinchuan City, Ningxia Hui Autonomous Region, Yinchuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2692-5437</Identifier><AffiliationInfo><Affiliation>National Laboratory for poliomyelitis, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety and National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088603" MajorTopicYN="N">Antigenic Drift and Shift</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="Y">Immunologic Deficiency Syndromes</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antigenic drift</Keyword><Keyword MajorTopicYN="N">molecular evolution</Keyword><Keyword MajorTopicYN="N">type 3 immunodeficiency vaccine-derived poliovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36224711</ArticleId><ArticleId IdType="doi">10.1002/jmv.28215</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Knowles NJ, Hovi T, Hyypi&#xe4; T, et al. Picornaviridae.Virus taxonomy: classification and nomenclature of viruses: Ninth Report of the International Committee on Taxonomy of Viruses. In: King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ, Diego., ed. Elsevier; 2011:855-880.</Citation></Reference><Reference><Citation>Katz SL. From culture to vaccine--salk and sabin. N Engl J Med. 2004;351(15):1485-1487.</Citation></Reference><Reference><Citation>Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009;27(20):2649-2652.</Citation></Reference><Reference><Citation>Johnson Muluh T, Hamisu AW, Craig K, et al. Contribution of environmental surveillance toward interruption of poliovirus transmission in Nigeria, 2012-2015. J Infect Dis. 2016;213(Suppl 3):S131-S135.</Citation></Reference><Reference><Citation>Dyer O. Polio: WHO declares type 3 poliovirus eradicated after 31 year campaign. BMJ. 2019;367:l6201.</Citation></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options. J Infect Dis. 2021;224:1529-1538.</Citation></Reference><Reference><Citation>Molodecky NA, Usman A, Javaid A, et al. Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy. Vaccine. 2021;39(15):2124-2132.</Citation></Reference><Reference><Citation>Ming LC, Hussain Z, Yeoh SF, Koh D, Lee KS. Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication. Global Health. 2020;16(1):63.</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283-S293.</Citation></Reference><Reference><Citation>Zhang Y, Zhu S, Yan D, et al. Type I vaccine-derived polioviruses in China from 1995 to 2019. Biosaf&#xa0; Health. 2019;1(3):155-158.</Citation></Reference><Reference><Citation>Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235-1242.</Citation></Reference><Reference><Citation>Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696-1701.</Citation></Reference><Reference><Citation>Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188(12):1845-1852.</Citation></Reference><Reference><Citation>Alexander JP Jr., HE Gary Jr., Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175(Suppl 1):S176-S182.</Citation></Reference><Reference><Citation>Macklin G, Diop OM, Humayun A, et al. Update on Immunodeficiency-Associated Vaccine-Derived polioviruses-worldwide, July 2018-December 2019. MMWR Morb Mortal Wkly Rep. 2020;69(28):913-917.</Citation></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-Eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLoS Pathog. 2015;11(8):e1005114.</Citation></Reference><Reference><Citation>Xu W, Zhang Y. Isolation and characterization of Vaccine-Derived polioviruses, relevance for the global polio eradication initiative. Methods Mol Biol. 2016;1387:213-226.</Citation></Reference><Reference><Citation>Sun H, Harrington C, Gerloff N, et al. Validation of a redesigned pan-poliovirus assay and real-time PCR platforms for the global poliovirus laboratory network. PLoS ONE. 2021;16(8):e0255795.</Citation></Reference><Reference><Citation>Yan D, Zhang Y, Zhu S, et al. Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China. Clin Vaccine Immunol. 2014;21(7):1012-1018.</Citation></Reference><Reference><Citation>Tamura K, Stecher G, Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. Mol Biol Evol. 2021;38(7):3022-3027.</Citation></Reference><Reference><Citation>Han Z, Zhang Y, Huang K, et al. Genetic characterization and molecular epidemiological analysis of novel enterovirus EV-B80 in China. Emerg Microbes Infect. 2018;7(1):193.</Citation></Reference><Reference><Citation>Bouckaert R, Vaughan TG, Barido-Sottani J, et al. BEAST 2.5: an advanced software platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2019;15(4):e1006650.</Citation></Reference><Reference><Citation>Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new heuristics and parallel computing. Nature Methods. 2012;9(8):772.</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on Vaccine-Derived poliovirus outbreaks-worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691-1699.</Citation></Reference><Reference><Citation>Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol. 2004;78(20):11097-11107.</Citation></Reference><Reference><Citation>Avanzino BC, Jue H, Miller CM, Cheung E, Fuchs G, Fraser CS. Molecular mechanism of poliovirus Sabin vaccine strain attenuation. J Biol Chem. 2018;293(40):15471-15482.</Citation></Reference><Reference><Citation>Minor PD, Dunn G, Evans DM, et al. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol. 1989;70(Pt 5):(5) 1117-1123.</Citation></Reference><Reference><Citation>Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63(63):1338-1344.</Citation></Reference><Reference><Citation>Omata T, Kohara M, Kuge S, et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol. 1986;58(2):348-358.</Citation></Reference><Reference><Citation>Shaw J, Jorba J, Zhao K, et al. Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak. J Virol. 2018;92(9):e01949-17.</Citation></Reference><Reference><Citation>Sanders BP, de Los Rios Oakes I, van Hoek V, et al. Cold-Adapted viral attenuation (CAVA): highly temperature sensitive polioviruses as novel vaccine strains for a next generation inactivated poliovirus vaccine. PLoS Pathog. 2016;12(3):e1005483.</Citation></Reference><Reference><Citation>Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol. 2008;82(9):4429-4440.</Citation></Reference><Reference><Citation>Blomqvist S, Savolainen C, Laine P, et al. Characterization of a highly evolved Vaccine-Derived poliovirus type 3 isolated from sewage in Estonia. J Virol. 2004;78(9):4876-4883.</Citation></Reference><Reference><Citation>Yakovenko ML, Cherkasova EA, Rezapkin GV, et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol. 2006;80(6):2641-2653.</Citation></Reference><Reference><Citation>Zhang Y, Yan D, Zhu S, et al. An insight into recombination with enterovirus species C and nucleotide G-480 reversion from the viewpoint of neurovirulence of Vaccine-Derived polioviruses. Sci Rep. 2015;5:17291.</Citation></Reference><Reference><Citation>Pliaka V, Kyriakopoulou Z, Tsakogiannis D, et al. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains. Eur J Clin Microbiol Infect Dis. 2010;29(12):1513-1523.</Citation></Reference><Reference><Citation>Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M. Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J Gen Virol, 902009:1859-1868.</Citation></Reference><Reference><Citation>Barbara H, Sophie J, Claire M, Bruno B, Marie-Line J, Francis D. Nonhomologous recombination between defective poliovirus and coxsackievirus genomes suggests a new model of genetic plasticity for picornaviruses. mBio. 2014;5(4):01119-01114.</Citation></Reference><Reference><Citation>Nicolas C, Barbara H, Marie-Line J, Florence CG, Francis D. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses. 2011;3(8):1460-1484.</Citation></Reference><Reference><Citation>Zhang Y, Zhu S, Yan D, et al. Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region. PLoS ONE. 2010;5(12):e15300.</Citation></Reference><Reference><Citation>Tao Z, Wang H, Xu A, et al. Isolation of a recombinant type 3/type 2 poliovirus with a chimeric capsid VP1 from sewage in Shandong, China. Virus Res. 2010;150(1-2):56-60.</Citation></Reference><Reference><Citation>Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 2008;137(1):168-172.</Citation></Reference><Reference><Citation>Yang CF, Chen HY, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol. 2005;79(20):12623-12634.</Citation></Reference><Reference><Citation>Kitamura K, Shimizu H. The molecular evolution of type 2 Vaccine-Derived polioviruses in individuals with primary immunodeficiency diseases. Viruses. 2021;13(7):1407.</Citation></Reference><Reference><Citation>Asare E, Mugavero J, Jiang P, Wimmer E, Paul AV. A single amino acid substitution in poliovirus nonstructural protein 2CATPase causes conditional defects in encapsidation and uncoating. J Virol. 2016;90(14):6174-6186.</Citation></Reference><Reference><Citation>Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in Northern Nigeria. J Virol. 2013;87(9):4907-4922.</Citation></Reference><Reference><Citation>Paul AV, Mugavero J, Yin J, et al. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology. 2000;272(1):72-84.</Citation></Reference><Reference><Citation>Jenkins HE, R Bruce A, Alex G, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362(25):729-732.</Citation></Reference><Reference><Citation>Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis. 2008;197(10):1427-1435.</Citation></Reference><Reference><Citation>Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199(3):391-397.</Citation></Reference><Reference><Citation>Home C. Poliovirus infections in four unvaccinated children-Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep. 2005;294(21):2689-2691.</Citation></Reference><Reference><Citation>Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ. 2004;82(1):3-8.</Citation></Reference><Reference><Citation>Hagan JE, Wassilak SG, Craig AS, et al. Progress toward polio eradication - worldwide, 2014-2015. MMWR Morb Mortal Wkly Rep. 2015;64(19):527-531.</Citation></Reference><Reference><Citation>Guglielmi G. Africa declared free from wild polio - but vaccine-derived strains remain. Nature. 2020. doi:10.1038/d41586-020-02501-3</Citation></Reference><Reference><Citation>Ramirez Gonzalez A, Farrell M, Menning L, et al. Implementing the synchronized global switch from trivalent to bivalent oral polio Vaccines-Lessons learned from the global perspective. J Infect Dis. 2017;216(suppl_1):S183-S192.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>